SCHEMBL4408115

SCHEMBL4408115

Cn1c(C(=O)O)cc2nc(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)c21

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.47
MAPK10 P53779 1/20 0.44
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
MAPK13 O15264 2/20 0.42
MAPK12 P53778 2/20 0.42
MAPK11 Q15759 2/20 0.42
ALOX5 P09917 1/20 0.41
TGFBR1 P36897 1/20 0.41
CSNK1D P48730 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SRC P12931 1/20 0.41
BRAF P15056 1/20 0.41
KDR P35968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410172 0.91 MAPK14 (0.47) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4410204 0.90 MAPK14 (0.46) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4409114 0.88 HTR3A (0.47) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4417406 0.83 NAMPT (0.45) MAPK14MAPK10CSNK1DKDM4EALDH1A1
SCHEMBL4416310 0.83 MAPK14 (0.46) MAPK14MAPK10CSNK1D
SCHEMBL4410208 0.82 RAB9A (0.43) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL4409918 0.80 MAPK14 (0.48) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4408472 0.80 MAPK14 (0.48) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4412139 0.80 MAPK14 (0.48) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL4410497 0.78 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK10 34/4885CSNK2A2 122/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK10 34/4885CSNK2A2 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.